Terushige Iike
Corporate Officer/Principal at EISAI CO., LTD.
Terushige Iike active positions
| Companies | Position | Start | End |
|---|---|---|---|
| EISAI CO., LTD. | Corporate Officer/Principal | 01/04/1986 | - |
Career history of Terushige Iike
Former positions of Terushige Iike
| Companies | Position | Start | End |
|---|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Director/Board Member | 01/05/2018 | - |
| Chief Executive Officer | 01/05/2018 | - |
Statistics
International
| Japan | 2 |
| United States | 2 |
Operational
| Corporate Officer/Principal | 1 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectoral
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| EISAI CO., LTD. | Health Technology |
| Private companies | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Stock Market
- Insiders
- Terushige Iike
- Experience
